## EVIDENCE FOR A NEGATIVE ASSOCIATION BETWEEN SCHIZOPHRENIA AND A POLYMORPHISM IN THE INSULIN RECEPTOR SUBSTRATE-3 (*IRS-3*) GENE

## K. Melkersson<sup>1</sup>, B. Persson<sup>2</sup>

<sup>1</sup>Department of Molecular Medicine and Surgery, <sup>2</sup>Science for Life Laboratory, Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden

**Introduction:** Since there are clear indications that schizophrenia is a systemic disorder, we sought for a common molecular basis for schizophrenia abnormalities in brain and body. Our hypothesis was that an impaired insulin/ insulin-like growth factor signalling in cells might underlie changes in both brain and body in schizophrenia. In this regard, the intracellular insulin receptor substrates 1-4 proteins might be of interest to study genetically.

**Objective/aim:** In this study, we chose to investigate the insulin receptor substrate-3 (*IRS-3*) gene as a candidate gene in schizophrenia.

**Methods:** The *IRS-3* gene of 93 patients with the diagnosis of schizophrenia according to DSM-IV criteria and 57 healthy control subjects was screened for DNA sequence variations, followed by case-control analyses of total 10 detected polymorphisms.

**Results:** The A/G genotype of the single nucleotide polymorphism (SNP) at position 100166597 in the *IRS-3* gene occurred in 5.3% of the control subjects compared with in 0% of the patients (p=0.05).

**Conclusion:** Our finding suggests that individuals carrying the A allele of this A/G SNP in the *IRS-3* gene have a protection against schizophrenia development.